New CMO hops onto Bicycle Therapeutics
pharmafile | September 26, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | AstraZeneca, Bicycle Therapeutics, GSK, Pfizer, biotech, drugs, pharma, pharmaceutical
Bicycle Therapeutics has moved to appoint industry veteran, Maria Koehler, to the position of Chief Medical Officer at the company. The biotech is focused on developing therapies through bicyclic peptide product platform and bringing Koehler to the team should boost the acumen the company boasts.
Koehler has spent much of her career at pharma giants, working for AstraZeneca, GSK and Pfizer. In particular, she worked at AstraZeneca for seven years and attained the role of Senior Medical Director – a role she held alongside a position as Staff member and Consulting Physician at Al DuPont Hospital. At GSK, she worked as Executive Director of Oncology for four years before making the move to Pfizer.
Koehler’s career at Pfizer spanned over 12 years and her last role, before leaving to join Bicycle Therapeutics, was as Vice President of Oncology Strategy, Innovation and Collaborations. Beyond this, she has been the author of more than 160 peer reviewed publications and book chapters.
“We are delighted to welcome Maria to the Bicycle leadership team. As Chief Medical Officer, she will play a pivotal role in furthering our mission to transform the treatment regimens for cancer and other diseases,” said Kevin Lee, Chief Executive Officer of Bicycle Therapeutics. “Maria has an exemplary track record, both as an oncology clinician and researcher, and as a drug development expert.”
“This is a tremendous opportunity to contribute to the clinical development of Bicycles, which are a truly innovative new class of cancer treatment with broad potential to make a life-changing impact on patients with cancer,” said Koehler, in explaining her own decision to join Bicycle. “I’m eager to work with the Bicycle team to bring these unique and powerful therapies to patients.”
Related Content
GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis
GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …
Cellbyte raises $2.75m to fund pharma drug launch platform
Cellbyte has announced that it has raised $2.75m in seed funding for the streamlining of …
Lilly opens fourth US Gateway Labs site
Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …
